Status:
COMPLETED
A Study of NKTR-358 (LY3471851) in Healthy Participants
Lead Sponsor:
Nektar Therapeutics
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.
Detailed Description
LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex...
Eligibility Criteria
Inclusion
- Overtly healthy males and females, as determined by medical history and physical examination
- Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²)
Exclusion
- Previous or current autoimmune disease/disorder
- Current active bacterial, viral, or fungal infection
- Administration of an inactivated vaccine within two weeks of study drug administration or live attenuated vaccine within 90 days of dosing .
Key Trial Info
Start Date :
March 19 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04380324
Start Date
March 19 2017
End Date
January 20 2019
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences
Lenexa, Kansas, United States, 66219